Proteomics and Genomics Combined With CT to Predict CVD

Overview

This study evaluates plaque progression and characteristics in patients with coronary atherosclerosis.

Registry

clinicaltrials.gov

Start Date

January 12, 2023

End Date

June 1, 2026

Last Updated

7 months ago

Study Type

Observational

Sex

All

Sponsor

Responsible Party

Principal Investigator

E.S.stroes

Principal Investigator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

•Renal insufficiency, defined as eGFR \< 30 ml/min
•History of cardiovascular events (myocardial infarction, peripheral artery disease and ischemic stroke)
•Use of lipid lowering therapy other than statin, ezetimibe or bempedoic acid monotherapy
•Change in lipid lowering therapy in the last 6 months
•Use of more than two antihypertensive agents
•No coronary atherosclerosis at baseline imaging
•Active malignancy requiring treatment
•Atrial fibrillation
•Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
•Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.

Coronary Artery Disease Progression

Time Frame: Through study completion, between 130-156 weeks

Presence of obstructive stenosis(Through study completion, between 130-156 weeks)
Calcified plaque volume progression(Through study completion, between 130-156 weeks)
Change in Pericoronary Adipose Tissue CT-Attenuation(Through study completion, between 130-156 weeks)
Non-calcified plaque volume progression(Through study completion, between 130-156 weeks)
Progression in number of high-risk plaque characteristics (yes/no)(Through study completion, between 130-156 weeks)
Progression in number of significant (>50%) and severe (>70%) stenoses(Through study completion, between 130-156 weeks)
Total plaque volume progression(Through study completion, between 130-156 weeks)
Low-attenuation plaque volume progression(Through study completion, between 130-156 weeks)
CAD-RADS progression (yes/no)(Through study completion, between 130-156 weeks)